The purpose of this retrospective study, the largest unselected series in our country, was to illustrate the clinicopathological features of non-Hodgkin’s lymphoma (NHL) classified according to the World Health Organization (WHO) classification of lymphoid neoplasms. A retrospective analysis was conducted and clinical features of histological subtypes were established in 810 patients (age ≧15 years) with NHL who were treated at 8 major centers representative of Greece. There were 435 males and 375 females 95% of them aged >30 years. B symptoms were present in 34% of the patients, while 45.3% had stages I–II and 54.6% had stages III–IV. LDH was increased in 37% of the patients. B cell lymphomas formed 88% of the cases whereas T cell lymphomas formed 12% of the total. Indolent lymphomas accounted for 31.1%, aggressive ones for 66.7% and very aggressive ones for 2.4% of all NHLs. Among indolent lymphomas extranodal ones (MALT B cell lymphoma) were the most common subset while follicular lymphoma grade I and II and small lymphocytic ones presented with equal frequency. Among the aggressive lymphomas diffuse large cell lymphoma (DLCL) was the most common subtype; this entity along with large-cell immunoblastic lymphomas accounted for 45.2% of all B cell lymphomas. Among the T cell lymphomas, peripheral T cell lymphomas and anaplastic large cell lymphomas of the T/null-cell type were the most common subtypes. The most common extranodal presentation was the gastrointestinal tract (GI). Next in frequency were primary extranodal NHL of the head and neck region. MALT B cell lymphomas were found in almost half of the patients with GI tract NHL, whereas in all other extranodal places DLCL was the predominant histological subtype. The median survival for indolent and aggressive NHL was 123.5 and 55.5 months, respectively. This is the first report of a large series of malignant lymphomas in Greece using the WHO classification. It appears that there are no significant differences between NHL in Greece and other large series as far as clinical and extranodal presentation is concerned. The frequency of follicular lymphoma in the current study is comparable to that reported from Asian countries and mainland Europe, but lower than that of US and Northern European series. There were no important differences in the incidence of the remaining histological subtypes between Greece and other European countries.

Keywords:
Greece, Non-Hodgkin’s lymphoma, WHO classification
1.
Weisenburger DD: Epidemiology of non-Hodgkin’s lymphoma: Recent findings regarding an emerging epidemic. Ann Oncol 1994;5(suppl I):19–24.
2.
Baris P, Zahm SH: Epidemiology of lymphomas. Curr Opin Oncol 2000;12:383–394.
3.
Anderson JR, Armitage JO, Weisenburger DD: Epidemiology of the non-Hodgkin’s lymphomas: Distributions of the major subtype differ by geographic locations. Ann Oncol 1998;9:717–720.
4.
Naresh KN, Srinivas V, Soman CS: Distribution of non-Hodgkin’s lymphoma in India: A study of 2773 lymphomas using REAL and WHO classification. Ann Oncol 2000;11(suppl I):63–68.
5.
National Cancer Institute sponsored study of classifications on non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Pathologic Classification Project. Cancer 1982;49:2112–2135.
6.
Lennert K, Mohri N: Histopathology and diagnosis of non-Hodgkin’s lymphomas; in Lennert K (ed): Malignant Lymphomas other than Hodgkin’s Disease. Berlin, Springer, 1978, pp 281–345.
7.
Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 1994;84:1361–1392.
8.
Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK: World Health Organisation classification of neoplastic diseases of hematopoietic and lymphoid tissues. Am J Surg Pathol 1997;21:114–121.
9.
Hiddemann W, Longo DL, Coiffier B, Fisher RI, Cabanillas F, Cavalli F, Nadler LM, De Vita VT, Lister TA, Amitage JO: Lymphoma classification – The gap between biology and clinical management is closing. Blood 1996;88:4085–4089.
10.
Non-Hodgkin’s Lymphoma Classification Project: A clinical evaluation of the international lymphoma study group classification of non-Hodgkin’s lymphoma. Blood 1997;89:3909–3918.
11.
Isobe K, Tamaru JI, Harigaya K, Mikata A, Ito H: Clinicopathologic evaluation of the revised European-American classification of lymphoid neoplasms (REAL) in Japan. Leuk Lymphoma 1999;34:143–149.
12.
Chuang SS, Lin CN, Li CY: Malignant lymphoma in southern Taiwan according to the Revised European-American classification of lymphoid neoplasms. Cancer 2000;89:1586–1592.
13.
Pileri SA, Zinzani PL, Went P, Pileri A, Bendandi M: Indolent lymphoma: The pathologist’s viewpoint. Ann Oncol 2004;15:12–18.
14.
Carbone P, Kaplan H, Musshoff K, Smithers DW, Tubiana M: Report of the committee on Hodgkin’s disease staging classification. Cancer Res 1971;31:1860–1861.
15.
D’Amore F, Christensen BE, Brincker H, Pedersen NT, Thorling K, Hastrup H, Pedersen M, Jensen MK, Johansen P, Andersen E, Bach B, Sorensen E: Clinicopathological features and prognostic factors in extranodal non-Hodgkin’s lymphomas. Eur J Cancer 1991;27:1201–1208.
16.
A predictive model for aggressive non-Hodgkin’s lymphoma: The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
17.
Morgan G, Vornanen M, Paitinen J, Naukkarinen A, Brincker H, Olsen J, Coeburgh JW, Vrints LWMA, Clayden D, McNally R, Jack A, Carli PM, Petrella T, Tomino RD, Lollo S, Barchielli A, Cartwright R: Changing trends in the incidence on non-Hodgkin’s lymphoma in Europe. Ann Oncol 1997;8(suppl II):49–54.
18.
Intragumtornchai T, Wannakrairoj P, Chaimongkol B, Bhoopat L, Lekhakula A, Thamprasit T, Suwanwela N, Suthipinthawong C, Prayoonwiwat W, Meekungwal P, Sirijerachai C, Pairojkul C: Non-Hodgkin’s lymphoma in Thailand. A retrospective pathologic and clinical analysis of 1,391 cases. Cancer 1996;78:1813–1819.
19.
Glass AG, Karnel LH, Menck HR: The national cancer data base report of non-Hodgkin’s lymphoma. Cancer 1997;80:2311–2320.
20.
D’Amore F, Brinker H, Gronbaek K, Thorling K, Pedersen M, Jensen MK, Andersen E, Pedersen NT, Mortensen LS: Non-Hodgkin’s lymphoma of the gastrointestinal tract: A population based analysis of incidence, geographic distribution, clinicopathologic presentation, features and prognosis. J Clin Oncol 1994;12:1673–1684.
21.
Ducreux M, Boutron MC, Piard F, Cardi PM, Faivre J: A 15-year series of gastrointestinal non-Hodgkin’s lymphomas: A population-based study. Br J Cancer 1998;77:511–514.
22.
Economopoulos T, Asprou N, Stathakis N, Papageorgiou E, Dervenoulas J, Xanthaki K, Raptis S: Primary extranodal non-Hodgkin’s lymphoma in adults: Clinicopathologic and survival characteristics. Leuk Lymphoma 1996;21:131–136.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.